BEIGENE (688235.SH) announced its financial results for the first quarter of 2026. The company reported product revenue of 10.321 billion yuan, representing a year-on-year increase of 29.3%. Total operating revenue for the quarter reached 10.544 billion yuan, up 31.0% compared to the same period last year. Net profit attributable to owners of the parent company was 1.608 billion yuan.

As of the end of the reporting period, the company's total assets stood at 59.069 billion yuan, an increase of 3.1% from the beginning of the period. Equity attributable to owners of the parent company was 33.031 billion yuan, rising 7.8% from the start of the quarter.

The growth in product revenue, which increased from 7.985 billion yuan in the prior-year period to 10.321 billion yuan, was primarily driven by increased sales of BRUKINSA® (zanubrutinib), products licensed from Amgen, and TEVIMBRA® (tislelizumab).

In the first quarter of 2026, global sales of BRUKINSA totaled 7.598 billion yuan, a year-on-year increase of 33.5%. The United States remained the company's largest commercial market, with sales reaching 5.283 billion yuan, up 30.8%. Sales in Europe totaled 1.266 billion yuan, growing 51.4%, while sales in China amounted to 651 million yuan, increasing 10.4%.

Global sales of TEVIMBRA for the quarter totaled 1.429 billion yuan, a 14.8% year-on-year increase. Sales of products licensed from Amgen reached 989 million yuan, rising 20.9% compared to the first quarter of 2025.